F Conti Selected Research

Breast Neoplasms (Breast Cancer)

1/2009	[Adjuvant chemotherapy in hormone-receptor positive HER2-negative early breast cancer].
1/2009	[Role of adjuvant chemotherapy in the choice of chemotherapeutic treatment of metastatic breast cancer].
9/2007	[Neoadjuvant endocrine therapy for locally advanced breast cancer].
7/2007	[High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
1/2007	[New combination chemotherapy regimens in the primary treatment of operable breast cancer].
3/2006	High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients.
7/2003	[Chemotherapy in the treatment of breast carcinoma].
7/2001	Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
1/2001	Docetaxel in patients with anthracycline-resistant advanced breast cancer.
1/2000	First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

F Conti Research Topics

Disease

13	Neoplasms (Cancer) 01/2015 - 03/2000
12	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2020 - 01/2000
11	Rheumatoid Arthritis 01/2022 - 08/2002
11	Inflammation (Inflammations) 01/2019 - 07/2006
11	Fibrosis (Cirrhosis) 01/2018 - 03/2009
10	Breast Neoplasms (Breast Cancer) 01/2009 - 01/2000
9	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 01/2008
9	Autoimmune Diseases (Autoimmune Disease) 01/2019 - 01/2009
8	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2019 - 01/2003
5	Hepatitis C 01/2019 - 09/2009
5	Hypersensitivity (Allergy) 04/2013 - 07/2006
4	Thrombosis (Thrombus) 01/2019 - 01/2000
4	Atherosclerosis 04/2012 - 01/2010
3	Arthritis (Polyarthritis) 08/2018 - 02/2010
3	Infections 01/2008 - 06/2001
3	Necrosis 01/2008 - 08/2002
2	Ascites 01/2018 - 03/2009
2	Neoplasm Metastasis (Metastasis) 01/2018 - 07/2001
2	Obesity 04/2013 - 07/2011
2	Leukemia 10/2011 - 05/2006
2	Asthma (Bronchial Asthma) 04/2011 - 07/2010
2	Liver Diseases (Liver Disease) 12/2010 - 03/2009
2	Atherosclerotic Plaque (Atheroma) 01/2010 - 04/2009
2	End Stage Liver Disease 10/2009 - 03/2009
2	Parasitic Diseases (Parasitic Disease) 10/2009 - 01/2008
2	Alcoholism (Alcohol Abuse) 01/2009 - 09/2006
2	Lung Neoplasms (Lung Cancer) 10/2007 - 07/2007
1	COVID-19 12/2021
1	Liver Neoplasms (Liver Cancer) 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2019
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2019
1	Toxic Optic Neuropathy 09/2018
1	Lupus Nephritis 09/2018
1	Macular Degeneration (Age-Related Maculopathy) 09/2018
1	Discoid Lupus Erythematosus 09/2018

Drug/Important Bio-Agent (IBA)

16	CytokinesIBA 01/2022 - 06/2001
14	AntibodiesIBA 01/2019 - 01/2000
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 08/2002
5	Antiviral Agents (Antivirals)IBA 01/2019 - 01/2017
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2010
5	CholesterolIBA 07/2013 - 03/2009
4	AutoantibodiesIBA 01/2020 - 03/2006
4	AnthracyclinesIBA 01/2009 - 01/2000
3	EnzymesIBA 01/2019 - 04/2005
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 10/2007
3	Ribavirin (Virazole)FDA LinkGeneric 01/2018 - 01/2017
3	InterferonsIBA 10/2017 - 01/2009
3	GlucocorticoidsIBA 06/2016 - 01/2008
3	Antiphospholipid AntibodiesIBA 06/2016 - 04/2005
3	Phospholipids (Phosphatides)FDA LinkGeneric 05/2016 - 01/2000
3	AntioxidantsIBA 04/2013 - 07/2006
3	Biological ProductsIBA 01/2013 - 01/2009
3	Interleukin-33IBA 07/2012 - 01/2009
3	InterleukinsIBA 04/2011 - 08/2002
2	Phosphotransferases (Kinase)IBA 01/2022 - 10/2011
2	Pharmaceutical PreparationsIBA 12/2021 - 09/2018
2	AlbuminsIBA 01/2021 - 03/2009
2	BilirubinIBA 01/2021 - 03/2009
2	Thromboplastin (Tissue Factor)IBA 01/2019 - 06/2003
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 07/2012
2	DNA (Deoxyribonucleic Acid)IBA 08/2018 - 01/2010
2	Rheumatoid FactorIBA 01/2018 - 11/2015
2	Glycoproteins (Glycoprotein)IBA 05/2016 - 04/2005
2	ImmunosorbentsIBA 05/2016 - 04/2005
2	Amino Acids FDA Link 02/2015 - 05/2006
2	Peptides (Polypeptides)IBA 02/2015 - 02/2015
2	Immunoglobulin G (IgG)IBA 02/2015 - 02/2015
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2013 - 04/2013
2	NeuropeptidesIBA 07/2013 - 07/2010
2	Interleukin-1 (Interleukin 1)IBA 01/2013 - 07/2012
2	Interleukin-9 (Interleukin 9)IBA 07/2012 - 04/2011
2	Interleukin-6 (Interleukin 6)IBA 07/2012 - 07/2006
2	Interleukin-13IBA 07/2012 - 08/2002
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2011 - 07/2011
2	ChemokinesIBA 07/2011 - 01/2009
2	Interleukin-4 (Interleukin 4)IBA 04/2011 - 12/2010
2	Monoclonal AntibodiesIBA 02/2010 - 03/2000
2	Tumor Biomarkers (Tumor Markers)IBA 03/2009 - 07/2001
2	Docetaxel (Taxotere)FDA Link 01/2009 - 01/2001
2	Taxoids (Taxanes)IBA 01/2009 - 01/2009
2	Hormones (Hormone)IBA 01/2009 - 09/2007
2	Infliximab (Remicade)FDA Link 12/2008 - 08/2002
2	Paclitaxel (Taxol)FDA LinkGeneric 03/2006 - 01/2000
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 03/2006 - 01/2001
1	Tyrosine (L-Tyrosine)FDA Link 01/2022
1	tofacitinibIBA 01/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2021
1	lenvatinibIBA 01/2021
1	Protein Isoforms (Isoforms)IBA 04/2019
1	UbiquitinIBA 01/2019
1	Antimalarials (Antimalarial Agents)IBA 09/2018
1	Retinaldehyde (Retinal)IBA 09/2018
1	SS-A antibodiesIBA 08/2018

Therapy/Procedure

14	Therapeutics 01/2021 - 01/2000
9	Liver Transplantation 01/2019 - 03/2000
9	Drug Therapy (Chemotherapy) 01/2009 - 01/2000
4	Adjuvant Chemotherapy 01/2009 - 01/2007
3	Neoadjuvant Therapy 09/2007 - 07/2001
2	Biological Therapy 01/2013 - 02/2010
2	Contraindications 09/2007 - 01/2000